Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 8/20 | 0.39 |
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HTR2B | P41595 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3602867 | 0.99 | ALOX5 (0.42) | ALOX5MGLLHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3609828 | 0.86 | SLC6A2 (0.39) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3610738 | 0.84 | HTR2A (0.39) | MGLLHTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL3597579 | 0.84 | ADRB1 (0.48) | ALOX5 | |
| Hydrochloric Acid SCHEMBL3603537 | 0.83 | ADRB1 (0.47) | ALOX5 | |
| Hydrochloric Acid SCHEMBL3592338 | 0.82 | DDB1 (0.35) | HTR2AHTR2CHTR2BCYP3A4SLC6A2 | |
| SCHEMBL4266777 | 0.82 | ATM (0.52) | ALOX5 | |
| Hydrochloric Acid SCHEMBL3599255 | 0.81 | HTR2C (0.40) | ALOX5MGLLHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3605372 | 0.81 | HTR2C (0.48) | ALOX5HTR2AHTR2CHTR2BCYP3A4 | |
| Hydrochloric Acid SCHEMBL3604632 | 0.81 | DDB1 (0.44) | HTR2AHTR2CHTR2BCYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | claimed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | claimed |
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | ALOX5 825/4885MGLL 3843/4885HTR2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.